Sphingosine kinase inhibition alleviates endothelial permeability induced by thrombin and activated neutrophils.
Inflammation and microvascular thrombosis are interrelated causes of acute lung injury in the systemic inflammatory response syndrome. Neutrophils (polymorphonuclear neutrophil [PMN]) and endothelial cells (EC) activated by systemic inflammatory response syndrome interact to increase pulmonary vascular permeability, but the interactions between PMN and EC are difficult to study. Recently, we reported that sphingosine 1-phosphate is a second messenger eliciting store-operated calcium entry (SOCE) in response to inflammatory agonists in both PMN and EC. Store-operated calcium entry is therefore a target mechanism for the therapeutic modulation of inflammatory PMN-EC interactions. Here, we isolated, modeled, and studied the effects of pharmacologic SOCE inhibition using real-time systems to monitor EC permeability after exposure to activated PMN. We created systems to continuously assess permeability of human pulmonary artery endothelial cells and human microvascular endothelial cells from lung. Endothelial cells show increased permeability after challenge by activated PMN. Such permeability increases can be attenuated by exposure of the cocultures to sphingosine kinase (SK) inhibitors (SKI-2, N,N-dimethylsphingosine [DMS]) or Ca2+ entry inhibitors (Gd3+, MRS-1845). Human microvascular endothelial cells from lung pretreated with SKI-2 or DMS showed decreased permeability when later exposed to activated PMN. Likewise, when PMNs were activated with thapsigargin (TG) in the presence of SKI-2, DMS, Gd, or MRS-1845, their ability to cause EC permeability subsequently was reduced. SKI-2 also inhibited the activation of human pulmonary artery ECs by thrombin. These studies will provide a firm mechanistic foundation for understanding how systemic SOCE inhibition may be used to prevent acute lung injury in vivo.
Itagaki
Kiyoshi
K
Department of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. kitagaki@bidmc.harvard.edu
Zhang
Qin
Q
Hauser
Carl J
CJ
D000627:Aminophenols / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002199:Capillary Permeability / Q000187:drug effects*; D002478:Cells, Cultured; D003199:Computer Systems; D042783:Endothelial Cells / Q000378:metabolism; D005682:Gadolinium / Q000494:pharmacology; D006801:Humans; D009504:Neutrophils / Q000378:metabolism / Q000502:physiology*; D009568:Nitrendipine / Q000031:analogs & derivatives / Q000494:pharmacology; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors*; D013110:Sphingosine / Q000031:analogs & derivatives / Q000494:pharmacology; D019284:Thapsigargin / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology*; D000099157:Sphingosine Kinase
D000627:Aminophenols; D002118:Calcium; D005682:Gadolinium; D009568:Nitrendipine; D017853:Phosphotransferases (Alcohol Group Acceptor); D013110:Sphingosine; D019284:Thapsigargin; D013844:Thiazoles; D013917:Thrombin; D000099157:Sphingosine Kinase; C525025:4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol; C503978:MRS 1845; C061800:N,N-dimethylsphingosine